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ABSTRACT 
Guidelines for the treatment of heart failure (HF) recommend the titration of beta-blockers (BB) to a 
target dosage shown to be effective in clinical trials. The benefit of BBs is associated with heart rate (HR) 
control, with a target resting HR<70 bpm which in clinical trials have been associated with improved 
clinical outcomes. The primary purpose of this study was to gauge the ability to achieve guideline-
directed medical therapy HR control in the early post-hospitalization period for HF patients with the 
wearable cardioverter defibrillator (WCD), assessing whether the WCD could be used to evaluate HR 
both at rest and during activity to determine if targets were being met and to adequately direct clinical 
decision making. The WCD platform allows continuous recording of HR. To assess the guideline-directed 
therapy goals for reduction of resting HR, HR was evaluated both at rest (nighttime: midnight-7am; 
daytime: 7am-midnight), and during activity of daily living. HR data during activity of daily living (ADL) 
and rest were collected from patients with HF that wore the WCD for ≥ 5 weeks (n=1353) between 2015 
and 2017. First, 643,891 activity episodes from 1,353 patients were analyzed. Daytime and nighttime 
resting HRs significantly dropped from beginning to end of WCD use (day: 72.5 bpm vs. 69.0 bpm, 
p<0.0001; night: 68.1 vs. 64.3, p<0.0001). However, 43% of patients still had an average daytime resting 
HR ≥70 bpm during the last week of WCD use. When comparing an individual’s peak activity HR during 
the first week of WCD use to the last week, there was no difference (93.6 bpm vs. 94.1 bpm, p=0.23). 
During ADL, 31% of patients had a HR ≥100 bpm, 14% of patients had a HR ≥110 bpm, and 6% had a HR 
≥120 bpm. In conclusion, months after hospital discharge, 43% of patients did not meet guideline-
directed resting target HR control, indicating they may not have been effectively managed with BB. HR 
during ADL may have also been higher than preferred. Remote HR monitoring may help physicians to 
adequately titrate guideline directed medical therapy, thus improving clinical outcomes in HF patients. 
Keywords: Heart failure, wearable cardioverter defibrillator, heart rate, guideline directed medical 
therapy, beta-blockers 
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INTRODUCTION:  
HR is a marker of sympathetic and parasympathetic activities, and a higher resting HR may be a 
sign of autonomic dysfunction associated with heart failure (HF)1,2. HR is inversely related to mortality, 
regardless of known cardiac disease, with a reported 14% increase in cardiovascular death for every 10 
bpm increase in HR in the general population.3 Nighttime resting HR may be even more predictive of all-
cause mortality and cardiac events.4 Beta-blockers (BB) are standard therapy for patients with heart 
failure with reduced ejection fraction (HFrEF), and the benefit is, in part, due to lowering HR. In patients 
with HFrEF, a lower resting HR is associated with lower all-cause mortality, particularly for those in sinus 
rhythm.5 Although the heart failure guidelines focus on achieving adequate dosages shown to be 
effective in clinical trials (usually the highest doses as possible); actual HR is clinically used during the 
optimization period to advance dosage. Further, HF guidelines also recommend the use of ivabradine in 
patients already on maximum tolerated doses of BB who are in sinus rhythm with a resting HR of ≥70 
BPM.6,7   The wearable cardioverter defibrillator (WCD), typically used for the monitoring and treatment 
of harmful ventricular tachyarrhythmias, also provides remote HR monitoring. We hypothesized that 
resting HR derived from the WCD may be a direct measure of whether patients in the early post-
discharge period are being adequately treated with BBs or ivabradine. Our objective was to determine if 
WCD recordings provided a feasible method to assess resting HR as well as HR during activity of daily 
living (ADL) in order to determine if guideline-directed HR targets are being achieved in HF patients post-
hospitalization. 
  
METHODS: 
 This was a retrospective study for determination of resting HR and HR during activity in patients 
with HF. All subjects provided consent to use their data for quality monitoring and research. The study 
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was performed in agreement with good clinical practice guidelines and with the standards established 
for human experimentation by the Declaration of Helsinki. 
All European patients with heart failure or myocardial infarction with a low EF and prescribed 
the continuous monitoring enabled WCD for ≥ 5 weeks (n=1353), with valid activity and resting HR 
available, and had a known outcome of either death, ICD implantation, or EF improvement, between 
2015 and 2017 were included in this retrospective analysis. This cohort represented approximately 23% 
of the entire WCD patient population (approximately 6,000) during this time period.  
The WCD (LifeVest®, ZOLL, Pittsburgh, PA, USA) automatically detects and treats sustained 
ventricular tachycardia (VT) and ventricular fibrillation (VF). A detailed description of the WCD has been 
provided in prior publications and reviews.8-10 The WCD platform also allows for continuous recording of 
HR, activity, and body position via the ECG electrodes and a 3-axis accelerometer in the electrode belt. 
Only episodes with clean ECG data (no artifact) were used for collecting HR data. Second by second HR 
was calculated from the recorded continuous monitoring data. 
Rest was defined as a ≥30 minute period where the device accelerometer recorded <60 
milligravity (mG). Daytime was defined as being from 07:00 am to midnight and nighttime from midnight 
to 07:00 am.  Activity of daily living (ADL) episodes were defined as a contiguous period (≥ 60 secs) 
where the device accelerometer records a ≥ 60 mG mean amplitude deviation. Two such periods split by 
a gap shorter than 10 seconds were treated as a single contiguous period. Peak HR was defined by the 
90th percentile of HRs during activity. 
Resting HRs are reported as weekly medians. The percentage of patients below the 70 bpm 
(guideline recommended threshold) and also below 90 bpm was analyzed. 6,7 The 90 bpm resting HR 
threshold was chosen to represent a “very high” resting HR.   
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 The percentages of patients with significantly elevated HR during ADL were analyzed. Exercise 
therapy guidelines recommend the HR not exceed 20-30 BPM above resting HR.11,12 HRs that were ≥100 
bpm were divided into groups according to a HR increase of each 10 bpm. 
To determine whether resting HR was being well-controlled in these patients post-
hospitalization, and whether it improved over time with therapy, HR was compared from the first week 
of WCD use (BOU) to the last week of WCD use (EOU). 
Descriptive statistics were used to summarize the datasets. Categorical variables were 
expressed as numbers and percentages. All continuous variables are reported as mean ± standard 
deviation, or medians for non-parametric data. A paired T-Test was performed to determine differences 
between HR during the first week of use (beginning of use: BOU) and the last week of use (end of use: 
EOU).  A T-Test between two different populations was used determine differences between HR during 
the ADL at BOU/EOU. Data were considered statistically significant with a 2-sided p value ≤0.05.  
 
RESULTS: 
There were 1,353 patients who met inclusion criteria for analysis of resting HR and HR during 
ADL (Table 1).  Patients were prescribed and indicated for the WCD due to a low EF (≤ 35%), primarily 
from HF or post-myocardial infarction (MI) with percutaneous coronary intervention (PCI) or coronary 
artery bypass grafting (CABG). They wore the WCD for a median 21.2 hr/day over a median period of use 
of 73 days.  
Both the daytime and nighttime resting mean HRs dropped significantly from beginning to end 
of WCD use (day: 72.5 bpm vs. 69.0 bpm, p<0.0001; night: 68.1 vs. 64.3, p<0.0001)(Figure 1). When 
comparing daytime and nighttime resting HR, there was a slowing down of approximately 4-5 bpm at 
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nighttime, both at the BOU and EOU (each p <0.0001).  At the BOU, 55% and 40% of patients were ≥ 70 
bpm at rest during the daytime or nighttime, respectively (Figure 2). By the EOU, these numbers were 
43% and 28% during the daytime or nighttime, respectively. Regardless of time of day, less than 10% of 
patients had a resting HR ≥ 90 bpm at the BOU, reduced by half by the EOU. 
From the 1,353 patients, a total of 643,891 activity episodes were analyzed. The mean HR during 
ADL did not change from the BOU to EOU (93.6 bpm vs 94.1 bpm, respectively, p=n.s.)(Figure 3). During 
the first week and last week of WCD use, activity HR was ≥100 bpm in 30% and 31% of patients, 
respectively. 6% of patients had a peak activity HR that was ≥ 120 bpm and 3% a peak activity HR >130 
bpm at either BOU or EOU (Figure 4). 
DISCUSSION: 
  The current study analyzed a large cohort of patients wearing the WCD for HF with a low EF. 
Over the WCD prescription time, both daytime and nighttime HR decreased significantly. However, a 
significant percentage, 42% at daytime and 28% at nighttime, revealed resting HRs higher than 70 bpm 
thus, greater than the guideline-directed target. Conversely, HR during activity showed no significant 
difference from early after hospital discharge to 2 to 3 months later.  
The WCD is primarily useful for detecting and treating ventricular tachyarrhythmias. However, 
the most recent WCD platform also allows for continuous recording of HR, activity and body position via 
the ECG electrodes and a 3-axis accelerometer in the electrode belt. There are currently no published 
studies available investigating the diagnostic usefulness of the continuous WCD HR monitoring. The 
current study was able to illustrate that in patients utilizing the WCD, resting HRs could be reliably 
measured. Moreover, the WCD was also able to detect and measure the HR during activity of daily living 
and during directed exercise. Therefore, the WCD may have, in addition to the basic function of 
preventing sudden cardiac death, an additional advantage in the management of heart failure patients 
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in optimizing guideline directed medical therapy at the time of prescription. Further studies are needed 
to investigate this additional value of the WCD, especially regarding optimization of GDMT and thereby 
possibly reducing the need for final ICD implantation. Surprisingly, significant gaps continue to exist in 
use of GDMT for HFrEF despite numerous national quality improvement efforts (IMPROVE-HF).13,14 
Recently, it has been demonstrated that the use of WCD improves GDMT in patients with HFrEF 15. The 
current study extends this work and demonstrates the value of WCD use as a monitoring tool early post-
discharge to optimize GDMT. While using the WCD to monitor and report HR after a heart failure event 
can be directly used to adjust BB therapy, it may also serve as a reminder to the healthcare professionals 
to also assess the titration of other pharmacologic agents included in optimal guideline directed medical 
therapy.  
 The current study demonstrated the ability of the WCD diagnostic capability to measure resting 
HRs.  Moreover, between the beginning and the end of WCD use, a significant decrease in resting HRs 
was detected, which was evident during both daytime and nighttime. Temporal changes in HR, such as 
between doctor visits, are also predictive of outcomes in HF patients. 16 The magnitude of HR reduction 
plays an important role in the mortality benefit of BB. A meta-analysis looking at 23 BB trials found that 
for every resting HR reduction of 5 BPM with BB, there was an 18% reduction in the risk of death.19 
While HR reduction may not be the only mechanism by which BB provide mortality benefit, it can at 
least be viewed as a marker or measure of BB response. The importance of HR control is also supported 
by more recent studies with ivabradine, a newer therapeutic agent that works specifically by lowering 
HR in patients not effectively treated by BB. It appears that in patients with HFrEF taking both BB and 
ivabradine, that the magnitude of HR reduction is more important to outcome than the dose of BB.17 HR 
reduction is also significantly correlated with LVEF improvement with both BB and ivabradine.18,19  
The current study displays that at the end of WCD use 40% of patients at daytime and 28% at 
nighttime still had HRs >70 bpm.  Despite the limitations of this study (the actual rhythm of the patient 
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was unknown, WCD indication was not recorded in some patients, and there was no information 
regarding BB or ivabradine usage), it may be speculated that while a relevant proportion of the study 
cohort may have received an optimization of heart failure therapy, another large proportion of patients 
could be in need of further optimization to meet the HRHR target of 70 bpm. 
HF guidelines recommend the use of maximum tolerated doses of BB. Further, ivabradine should be 
added in patients already on maximum BB dosage, who are in sinus rhythm with a resting HR of ≥70 
BPM.6,7 Thus, the WCD may be an important tool in directing heart failure therapy. Also, the WCD may 
help to clarify more important questions, especially regarding the optimal HR target in atrial fibrillation 
and if there are differences in daytime and nighttime HRs. 
 Guidelines recommend a target resting HR <70 bpm.6,7 Currently, the guidelines do not 
distinguish between daytime and nighttime. Further, the guidelines recommend only a target resting HR 
but no target activity HR. The current study reports on both resting HR and HR during activity with the 
WCD. Therefore, we propose an additional benefit of the WCD as diagnostic tool, beside its function as 
prevention of sudden cardiac death. We propose that weekly measurements of resting HR may help to 
prompt optimization of GDMT. Therefore, further evaluation of the diagnostic features of the WCD is 
warranted to determine its effect on GDMT and cardiovascular endpoints like mortality.  
This analysis did not document the patient’s actual rhythm at all points of heart rate 
determination. Atrial fibrillation with an uncontrolled ventricular response could have accounted for 
some high heart rates, but those rates would still suggest lack of GDMT HR control. The WCD indication 
was not recorded in some patients. Since this was a retrospective observational study, the prescription, 
compliance, and dosage of BB or ivabradine usage was not collected. However, the use of real HR data 
may ultimately prove to be a superior method than collecting information from discharge summaries or 
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pharmacy claims data. Future prospective studies utilizing the WCD in patients with HFrEF should 
consider linking additional datasets to validate appropriate medication use and adherence. 
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TABLES and FIGURES 
 
Figure 1. Average resting HR at the beginning (BOU) and end of use (EOU) 
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Figure 2. Percentage of patients with resting HR below the thresholds of 70 bpm or 90 bpm at the 
beginning (BOU) and end of use (EOU). 
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Figure 3. Average HR during Activity of Daily Living (ADL) at the BOU and EOU 
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Figure 4. Percentage of patients with peak activity HR above 100 bpm at the beginning (BOU) and end of 
use (EOU). 
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Table 1.  Patient Characteristics for Group 1 (N=1353) 
Variable 
Median Age [IQR] (years) 58 [50 - 67] 
Male 1085 (80%) 
Median Length of use (days) 73 [53 - 91] 
[IQR]  
# of activities 643,891 
Diagnoses 
CHF 614 (45%) 
PCI/CABG/MI 537 (40%) 
Myocarditis 81 (6%) 
Heart transplant 4 (<1%) 
Others 117 (9%) 
CHF: congestive heart failure; PCI: percutaneous coronary 
intervention; CABG: coronary artery bypass graft; MI: 
myocardial infarction 
 
 
